CV Sciences (CVSI) Long-Term Investments (2013 - 2014)
CV Sciences (CVSI) posted Long-Term Investments of $400694.0 for Q1 2014, down 8.78% sequentially from $439246.0 in Q4 2013, and up 60.28% YoY from $250000.0 in Q1 2013.
CV Sciences (CVSI) Long-Term Investments (2013 - 2014) Analysis & Trends
CV Sciences has reported Long-Term Investments for 2 years, with the latest figure at $400694.0 in Q1 2014.
- Quarterly Long-Term Investments rose 60.28% year-over-year to $400694.0 in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $400694.0 (up 60.28% YoY) and the FY2013 annual result came in at $439246.0, changed N/A from the prior year.
- Long-Term Investments fell to $400694.0 in Q1 2014 per CVSI's latest filing, from $439246.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $650000.0 in Q3 2013 and troughed at $250000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 60.00 Mn |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 400,694.00 |
| Dec 31, 2013 | 439,246.00 |
| Sep 30, 2013 | 650,000.00 |
| Jun 30, 2013 | 500,000.00 |
| Mar 31, 2013 | 250,000.00 |